ReviewBioactive materials2027
Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight.
Review in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organoids, as three-dimensional bioactive microtissues capable of recapitulating native organ architecture and function, have become valuable models in biomedical research. However, their broad adoption is constrained by subjective morphological assessment and endpoint assays that compromise standardization and scalability. This review introduces Organoid Intelligent Morphomics (OIM), an integrative analytical framework that synergizes imaging technologies with artificial intelligence to establish a "morphology-function-mechanism" mapping. OIM enables a paradigm shift from qualitative to quantitative analysis, from static to dynamic monitoring, and from superficial observation to deep molecular inference. The applications of OIM are critically examined across three interconnected domains: (1) quality control, encompassing real-time assessment through non-invasive viability quantification and morphological evaluation, as well as predictive quality control for early differentiation outcome forecasting; (2) disease deconstruction, enabling quantitative, multiscale phenotyping of disease morphology and establishing morphology-mechanism association analyses; (3) drug development, facilitating high-throughput efficacy screening, toxicity assessment, and personalized therapeutic guidance. Furthermore, we critically analyze the current data, algorithmic, and translational challenges facing OIM, propose corresponding solutions, and provide a roadmap toward artificial intelligence virtual organoids. Ultimately, OIM holds promise for establishing the critical technological infrastructure for the scalable manufacturing and clinical translation of organoid-based therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.